B2BROKER-GROUP
26.8.2021 15:04:33 CEST | Business Wire | Press release
B2Broker Group is pleased to officially announce the launch of its venture fund, B2Broker VC. B2Broker VC is led by a team that is one of the most successful and fast-growing financial technology groups with in-depth expertise in sectors ranging from IT development to capital management. The venture fund will enable the investment in, and nurture of external projects that are of interest such as new fintech startups and payment systems, and will create synergies for the group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005497/en/
First Ventures
Back in 2017, like many other tech industry giants, B2Broker Group started working on its own internal corporate venture fund. This was focused on the development of a number of specific projects. Since then, the capitalisation of the group’s fund has grown steadily and now includes a number of projects in which the company has invested over $15 million so far. This is an exciting project which has enabled the development of a modern financial and technological ecosystem on the basis of the B2Broker group of companies.
Of particular focus is the launch of B2BinPay in 2017, a payment system which has become one of the most modern and technologically progressive platforms in the world, B2BX , a platform for the trading of digital assets which is licenced in the EU, Eqwire, a digital banking service, and last but not least, the group’s most expensive and complex project, B2Prime, which is an integrated liquidity provider with licences in different jurisdictions, including Europe and CIS.
External Projects
With the experience acquired on these internal projects and the business-processes that have been developed, B2Broker VC has also started investing in external projects. One of the most noteworthy of these is the innovative Coinsbuy, a project designed to cater for the growing demand for buying crypto using a credit or debit card. This will be a complementary project to B2Broker’s ecosystem.
Throughout this process, B2Broker VC identified the most interesting sectors such as fintech, IT development and automation, as well as startups offering products for the brokerage market.
Procedures and Stages
The most important aspect that the group seeks in its partners is conscientiousness, a clear vision and a good understanding of the market. B2Broker VC considers all potential recipients of investments as long-term strategic partners who in partnership, will move towards global leadership in the various market sectors.
B2Broker VC always finds the most convenient way of investment and cooperation both through equity holding and via convertible loans, which make the terms of cooperation as flexible as possible.
Companies who wish to apply for funding follow a step-by-step procedure starting with the preparation of an application and documents. This is followed by a product performance evaluation, follow-up questions and a series of meetings and evaluations before the final decision is made. After the signing of various documents and agreements, the first tranche of investment will be released after a process which takes between 2-6 months.
The kind of projects that are of interest to B2Broker VC are ones that match the group’s goals and business model. These include:
● Fintech development: Products and services for Forex, securities, derivatives, CFD and crypto markets.
● IT development: Development of payment systems, trading and brokerage platforms, risk management systems, analytical systems.
We are particularly interested in companies who have Bridges Technology and plugins for MT4/5, Trading Platforms for FX/CFD trading and those who have built trading platforms for Crypto Perpetual Futures, Crypto Spot trading and Securities trading on Exchanges. We are also looking for HUB and liquidity aggregation solutions and technology for market making on crypto exchanges.
● Automation: Products in the field of automation of external systems and process automation services.
● Products/services suitable for B2Broker's ecosystem such as KYC solutions, marketing services, products and services for the brokerage market.
Companies that end up working with the B2Broker Group will be handed the keys to the development of a young company that includes both financial assistance and access to the group’s infrastructure, its offices, and development teams, as well as top financial and marketing expertise.
Applications
B2Broker VC carefully considers each application received and investigates the possible mechanisms of cooperation, regardless of the size of the company and entrepreneurial experience among the founders.
To submit your application and become a global leader with B2Broker VC email us at vc@b2broker.com or visit our website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005497/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
